Lancet Neurology

Papers
(The H4-Index of Lancet Neurology is 84. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)
ArticleCitations
Clinical descriptors of disease trajectories in patients with traumatic brain injury in the intensive care unit (CENTER-TBI): a multicentre observational cohort study1483
Anti-CD19 CAR T cells for refractory myasthenia gravis1165
Comparison of amyloid burden in individuals with Down syndrome versus autosomal dominant Alzheimer's disease: a cross-sectional study1038
Lessons and future directions for GBA1-targeting therapies1035
Correction to Lancet Neurol 2025; 24: 850–65881
Increasing diversity in dementia research621
Traumatic brain injury research: homogenising heterogeneity611
Correction to Lancet Neurol 2022; 21: 42–52560
Correction to Lancet Neurol 2024; 23: 168–77550
Correction to Lancet Neurol 2021; 20: 448–59522
Correction to Lancet Neurol 2025; 24: 850–65464
Bailout intracranial angioplasty or stenting following thrombectomy for acute large vessel occlusion in China (ANGEL-REBOOT): a multicentre, open-label, blinded-endpoint, randomised controlled trial446
Implications of the KIWE trial for low-income and lower-middle-income countries435
Global burden of stroke: dynamic estimates to inform action398
A biological classification of Huntington's disease: the Integrated Staging System343
The gut microbiome, systemic inflammation, and autoimmunity in Parkinson's disease327
The relevance of social and commercial determinants for neurological health308
The predictive value and clinical use of the neurological pupillary index – Authors' reply304
Treatment-induced neuropathy of diabetes: an underdiagnosed entity – Authors' reply295
Resolution of expression of concern—Serotonergic pathology and disease burden in the premotor and motor phase of A53T α-synuclein parkinsonism: a cross-sectional study287
Multidisciplinary care for amyotrophic lateral sclerosis276
Safety and efficacy of early versus delayed acetylsalicylic acid after surgery for spontaneous intracerebral haemorrhage in China (E-start): a prospective, multicentre, open-label, blinded-endpoint, r271
Dementia diagnosis in the anti-amyloid era246
Continuous subcutaneous levodopa–carbidopa infusion for Parkinson's disease238
Correction to Lancet Neurol 2020; 19: 391–401236
RAB32 mutation in Parkinson's disease233
Parkinson's disease is a recognisable and useful diagnostic entity228
Surrogate endpoints for progressive multifocal leukoencephalopathy228
Gene therapy for X-linked myotubular myopathy: the challenges217
Diana Cejas201
Guiding the future of neurology: our peer-reviewers in 2025186
The Genetic Epidemiology of Parkinson's Disease view – Authors' reply185
Considering the neurological health needs of LGBTQIA people180
Elia M Pestana Knight178
Albert Kwaku Akpalu173
Beyond the modular brain173
A chilly tale of dementia166
A nasal CGRP receptor antagonist for acute migraine therapy162
A study in healing the wounds of trauma155
Trials in intracerebral haemorrhage: a path to success?147
Delving into the human mind145
Amyotrophic lateral sclerosis from genotoxins alone?143
Epilepsy syndromes: an essential piece of the puzzle143
2025 for neuromuscular diseases: a year of multiple advances140
Correction to Lancet Neurol 2022; 21: 284–94139
Correction to Lancet Neurol 2023; 22: 812–25138
The prescription of valproate: risk of harm132
From stroke awareness to stroke action awareness130
Aspiring to restore arm and hand function after stroke130
B cell-targeting chimeric antigen receptor T cells as an emerging therapy in neuroimmunological diseases129
Long-term safety, tolerability, and efficacy of eptinezumab in chronic cluster headache (CHRONICLE): an open-label safety trial128
Neuropathology of Alzheimer's disease after anti-amyloid β antibody treatment125
A sensitive portrayal of a controversial condition124
Global burden of headache disorders: innovations, disparities, and priorities for action122
Miratul Muqit: leading an alliance to decode Parkinson's disease120
Comparative effectiveness of cognitive behavioural therapy, modafinil, and their combination for treating fatigue in multiple sclerosis (COMBO-MS): a randomised, statistician-blinded, parallel-arm tri119
Intracranial pressure monitoring with and without brain tissue oxygen pressure monitoring for severe traumatic brain injury in France (OXY-TC): an open-label, randomised controlled superiority trial116
Functional or hysterical?115
Complex regional pain syndrome: advances in epidemiology, pathophysiology, diagnosis, and treatment115
Safety and efficacy of rituximab versus dimethyl fumarate in patients with relapsing-remitting multiple sclerosis or clinically isolated syndrome in Sweden: a rater-blinded, phase 3, randomised contro115
Cognitive function in people with functional seizures112
Comparative effectiveness of azathioprine and mycophenolate mofetil for myasthenia gravis (PROMISE-MG): a prospective cohort study112
The ATTeST trial in ataxia telangiectasia: some concerns – Authors' response112
Correction to Lancet Neurol 2024; 23: 110–22111
Correction to Lancet Neurol 2022; 21: 620–31111
Multiple sclerosis in 2022: old players, new insights110
A health literacy campaign for Parkinson's disease in Africa: a novel campaign to break down language barriers107
New results for risdiplam in spinal muscular atrophy106
Expansion of stenting indications in the USA103
Responsible innovation in neurology103
Jessica Ailani102
Exploring immunomodulation with azathioprine in Parkinson's disease100
α-synuclein seed amplification and its uses in Parkinson's disease99
A proposal for equity neuroscience98
Rethinking AI trials in brain health96
Safety and efficacy of intra-erythrocyte dexamethasone sodium phosphate in children with ataxia telangiectasia (ATTeST): a multicentre, randomised, double-blind, placebo-controlled phase 3 trial96
Changing multiple-sclerosis-induced thoughts and behaviours95
Learning to be an adult with a disability92
Supporting young carers across neurological disorders91
Neurological infections in 2023: surveillance and prevention90
Thank you to The Lancet Neurology's peer reviewers in 202589
Major advances in Parkinson's disease over the past two decades and future research directions86
Revisiting candesartan: new evidence for an old option in migraine prevention84
Indobufen versus aspirin in patients with acute ischaemic stroke in China (INSURE): a randomised, double-blind, double-dummy, active control, non-inferiority trial84
Effect of blood pressure-lowering agents on microvascular function in people with small vessel diseases (TREAT-SVDs): a multicentre, open-label, randomised, crossover trial84
0.10016489028931